The health sector’s spending on federal lobbying rose 70% from 2000 to 2020, driven mostly by pharmaceutical and health product manufacturers and providers, according to new research. U.S. healthcare ...
The RESECT study: Factors associated with overall survival (OS) and relapse-free survival (RFS) among patients with stages I–III resected NSCLC without known EGFR mutations.
Lobbyist spending across the healthcare sector increased by more than 70% from 2000 to 2020 after adjusting for rising prices, according to a recent peer-reviewed analysis. The lobbying dollars were ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results